Author: TokeTheMost

Cannabis industry organizations say they are cautiously looking forward to engaging with the newly elected Liberal government following the April 28 election.

A new Prime Minister and a new cabinet provide an opportunity for a beleaguered industry to renew engagement efforts to highlight issues such as excise tax reform, annual regulatory fees, and market and promotional restrictions, among many others. 

While Health Canada recently released a large package of regulatory changes addressing some long-standing industry issues, many of the larger issues remain long-term goals of the industry, especially the federally licensed cannabis producers. 

Paul McCarthy, President of the Cannabis Council of Canada, highlighted these concerns in a public statement on the election results and the general anxiety within the industry.

“Canada likes to position itself as a global leader in legal cannabis—but since legalization in 2018, the federal government has failed this industry and the tens of thousands of hardworking Canadians it supports,” said McCarthy. “With a new government in office, it’s time for action. The cannabis industry deserves the same attention and support as any sector of our economy.”  

Canada’s cannabis industry is a major driver of economic growth, notes McCarthy, contributing more than $43 billion to the national GDP since the beginning of legalization in 2018, with approximately $7.4 billion contributed in 2024 alone. 

The Council is calling for a change from an excise tax rate of $1 a gram to 10%, moving to a single harmonized excise stamp, and a more concerted effort to take on the still-present illicit cannabis market.

The CEO of New Brunswick’s Organigram Global Inc. also congratulated Carney on the results of the 2025 federal election while urging policymakers to better support Canada’s cannabis industry.

“Congratulations to Prime Minister Carney on his party’s victory and to Opposition Leader Pierre Poilievre for his party’s strong showing, as well as all who put themselves forward as candidates,” said Beena Goldenberg, CEO of Organigram.

“In this election, Canadians were asked to embrace a plan to build economic resilience against an increasingly unpredictable United States. Now it’s time for policymakers, industry leaders, and stakeholders to unite behind a shared goal: unlocking the full potential of Canada’s cannabis sector as a driver of innovation, job creation, and sustainable economic growth.”

Like C3, of which Organigram is a member, the company also lists moving from a $1 per gram excise rate to a 10% ad valorem rate, as well as encouraging more opportunities for inter-provincial and international trade. 

At the provincial level, Walker Patton, on behalf of the BC Cannabis Alliance, says the organization is excited to begin connecting with the new government to discuss options for moving the industry forward. Patton is the CcO at Woody Nelson, a cannabis producer based in eastern BC.

“We’re eager to see what an economy-focused leader will bring to the table, but the Liberals have a history of ignoring the challenges their policies have created for our industry, so we have mixed feelings,” Patton tells StratCann. “Regardless, we look forward to engaging with the country’s leadership on these issues in the pursuit of a stronger economy and bringing high-quality jobs back to small rural communities across the country.”

Related Articles

NASDAQ | TSX: ACB

Company’s Long-Standing Investment in Operational Excellence Continues with Industry Leading Upgrades and Renaming the Facility to Aurora Alpine

EDMONTON, AB, April 30, 2025 /CNW/ – Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces the completion of a multi-year investment of $3 million in improvements to its manufacturing facility in Pemberton, British Columbia. These upgrades are a combination of Aurora’s proprietary high-performing genetics and state-of-the-art engineering design which have resulted in optimal cultivation conditions, expanded output, and superior product quality. The site has been renamed to Aurora Alpine – a testament to the site reaching its highest potential and to reflect the facility overlooking Mount Currie in the Pemberton Valley.

“Over the last three years, the investments we’ve made into this facility have resulted in doubling the yield and potency, reaching a record 33.7%,” says Alex Miller, Executive Vice President of Operations and Supply Chain at Aurora. “The name Aurora Alpine reflects our commitment to achieving the highest degree of excellence at a site that’s driven by industry leading genetic technology, and backed by a world-class team that make it all possible.”

The former Whistler Medical Marijuana Company site was licensed in 2019 and was built on a legacy of producing award-winning cannabis. The GACP certified facility enables Aurora to expand its global reach by exporting premium medical cannabis produced from the Aurora Alpine site internationally.

Aurora continues to advance the frontiers of operational excellence through the integration of cutting-edge cultivation technologies and proprietary genetics. These advancements have not only increased manufacturing capabilities, but have also set new industry standards for operational efficiency and cultivation precision. These continuous improvements are what solidifies Aurora as a global leader that continues to shape the future of the cannabis industry.

About Aurora Cannabis Inc.

Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company’s adult-use brand portfolio includes Drift, San Rafael ’71, Daily Special, Tasty’s, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America’s leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora’s brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on X and LinkedIn.

Story Continues

Aurora’s common shares trade on the NASDAQ and TSX under the symbol “ACB”.

Contact

For Media: Michelle Lefler | VP, Communications & PR | media@auroramj.com

For Investors: ICR, Inc. | aurora@icrinc.com

Forward Looking Information

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements“). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company’s improvements at its facility located in Pemberton, BC and the anticipated benefits, including expanded capacity, superior growing practices, optimal cultivating conditions, and the ability for Aurora to expand its global reach by exporting premium medical cannabis produced from that facility internationally, as well as statements regarding the Company’s commitment to continuous improvement and operational excellence.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management’s estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management’s estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual information from dated June 20, 2024 (the “AIF”) and filed with Canadian securities regulators available on the Company’s issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC’s website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-announces-the-completion-of-a-multimillion-dollar-investment-and-renaming-of-bc-manufacturing-facility-302441872.html

SOURCE Aurora Cannabis Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2025/30/c3502.html

Following the solid earnings report from Decibel Cannabis Company Inc. (CVE:DB), the market responded by bidding up the stock price. Despite this, our analysis suggests that there are some factors weakening the foundations of those good profit numbers.

We’ve discovered 3 warning signs about Decibel Cannabis. View them for free.

To understand the value of a company’s earnings growth, it is imperative to consider any dilution of shareholders’ interests. In fact, Decibel Cannabis increased the number of shares on issue by 41% over the last twelve months by issuing new shares. That means its earnings are split among a greater number of shares. To talk about net income, without noticing earnings per share, is to be distracted by the big numbers while ignoring the smaller numbers that talk to per share value. You can see a chart of Decibel Cannabis’ EPS by clicking here.

How Is Dilution Impacting Decibel Cannabis’ Earnings Per Share (EPS)?

As it happens, we don’t know how much the company made or lost three years ago, because we don’t have the data. And even focusing only on the last twelve months, we don’t have a meaningful growth rate because it made a loss a year ago, too. But mathematics aside, it is always good to see when a formerly unprofitable business come good (though we accept profit would have been higher if dilution had not been required). So you can see that the dilution has had a fairly significant impact on shareholders.

In the long term, if Decibel Cannabis’ earnings per share can increase, then the share price should too. However, if its profit increases while its earnings per share stay flat (or even fall) then shareholders might not see much benefit. For that reason, you could say that EPS is more important that net income in the long run, assuming the goal is to assess whether a company’s share price might grow.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Our Take On Decibel Cannabis’ Profit Performance

Over the last year Decibel Cannabis issued new shares and so, there’s a noteworthy divergence between EPS and net income growth. For this reason, we think that Decibel Cannabis’ statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. On the bright side, the company showed enough improvement to book a profit this year, after losing money last year. At the end of the day, it’s essential to consider more than just the factors above, if you want to understand the company properly. So while earnings quality is important, it’s equally important to consider the risks facing Decibel Cannabis at this point in time. To help with this, we’ve discovered 3 warning signs (2 make us uncomfortable!) that you ought to be aware of before buying any shares in Decibel Cannabis.

Today we’ve zoomed in on a single data point to better understand the nature of Decibel Cannabis’ profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to ‘follow the money’ and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

In the latest version of a lauded, long-running campaign called “I’m High Right Now,” modern elders pose their unfiltered questions about cannabis use, wondering if it can ease their joint pain or energize their love lives.

Yes, boomer!

The ads, having appeared consistently since their 2023 launch, are kicking off a second phase with media partner Meta, significantly broadening the potential reach of the weed advocacy message from Cannabis Media Council.

Through Facebook and Instagram posts, the new Q&A iteration of “I’m High Right Now” keeps its focus on the 55-plus demo that was influenced by the strident war-on-drugs rhetoric and yet has emerged as an active weed-consuming and canna curious audience.

The media buy, which will span the next full year and possibly beyond, proves that formerly verboten ad spaces are now making deals with weed players.

“Part of the point of launching this campaign with Meta is to show that it’s possible,” said Amy Deneson, CMC’s executive director and co-founder. “It’s not without complications or nuance, like anything involving cannabis, but these channels are open to us.”

The deal with Meta comes via media planning and buying agency Transparent eCom, which counts cannabis brands like Cookies, Herb, and Sunday Scaries among its larger client roster. Transparent handled a previous Meta placement of “I’m High Right Now” in its original iteration, which logged 250,000 impressions and 20,000 engagements, per CMC.

Widespread acceptance

While cannabis remains a federally illegal Class III drug, 39 U.S. states have legalized the plant for medical or recreational use (24 states allow both). The legal industry is expected to reach $35.3 billion in sales this year, per MJBiz Daily, with a total economic impact north of $123 billion. Meantime, public acceptance is at a peak, with 70% of Americans favoring legalization, according to Gallup.

LAS VEGAS, April 30, 2025 (GLOBE NEWSWIRE) — Planet 13 Holdings Inc. (CSE: PLTH) (OTCQX: PLNH) (“Planet 13” or the “Company”), a leading vertically-integrated multi-state cannabis company, today announced the grand opening of Planet 13 Edgewater on May 31, 2025, the Company’s 33^rd dispensary in Florida and 37^th nationwide. Located at 1308 S Ridgewood Ave, Edgewater, FL, the 3,000-square-foot facility will serve the growing medical cannabis community in East Central Florida and will be open Monday through Sunday from 9 a.m. to 7 p.m.

“We’re proud to bring the Planet 13 experience to Edgewater as we continue our growth across Florida,” said Bob Groesbeck, Co-CEO of Planet 13. “Situated on U.S. Highway 1, a major retail corridor, this location offers excellent accessibility for patients. As we expand, our focus remains on providing high-quality cannabis products and a best-in-class retail experience for the medical cannabis community across Volusia County and the surrounding metropolitan areas.”

Planet 13 Edgewater spans 3,000 square feet in a high-traffic retail plaza, benefiting from strong daily vehicle counts and a prime location alongside Taco Bell in a fully leased, dual-tenant property that ensures steady foot traffic and long-term stability. With a growing local population and increasing demand for retail and medical cannabis access, this location is well-positioned for sustained growth. As Planet 13 continues expanding its Florida presence, it remains committed to quality, innovation, and customer care, providing top-tier cannabis products and unparalleled service to patients across its retail footprint.

Visit Planet 13 Edgewater today and experience why Planet 13 is a leader in cannabis innovation.

About Planet 13
Planet 13 (https://planet13.com) is a vertically integrated cannabis company, with award-winning cultivation, production and dispensary operations across its locations in California, Nevada, Illinois, and Florida. Home to the nation’s largest dispensary, located just off The Strip in Las Vegas, Planet 13 continues to expand its footprint with the recent debut of its first consumption lounge in Las Vegas, DAZED!, the opening of its first Illinois dispensary in Waukegan, bringing unparalleled cannabis experiences to the Chicago metro area. Planet 13 operates 33 dispensaries across Florida, a key market in its expansive footprint, bringing its total to 37 locations nationwide. Planet 13’s mission is to build a recognizable global brand known for world-class dispensary operations and innovative cannabis products. Licensed cannabis activity is legal in the states Planet 13 operates in but remains illegal under U.S. federal law. Planet 13’s shares trade on the Canadian Securities Exchange (CSE) under the symbol PLTH and are quoted on the OTCQX under the symbol PLNH. To learn more, visit planet13.com and follow Planet 13 on Instagram @planet13stores.

Cautionary Note Regarding Forward-Looking Information
This news release contains forward-looking information and forward-looking statements within the meaning of applicable securities laws. All statements, other than statements of historical fact, are forward-looking statements and are often, but not always, identified by phrases such “plans”, “expects”, “proposed”, “may”, “could”, “would”, “intends”, “anticipates”, or “believes”, or variations of such words and phrases. In this news release, forward-looking statements relate to the announcement of a dispensary opening. Such forward-looking statements reflect what management of the Company believes, or believed at the time, to be reasonable assumptions and accordingly readers are cautioned not to place undue reliance upon such forward-looking statements and that actual results may vary from such forward-looking statements. These assumptions, risks and uncertainties which may cause actual results to differ include, among others, those assumptions, risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and any of the Company’s subsequent periodic reports filed with the U.S. Securities and Exchange Commission at www.sec.gov and on SEDAR+ at www.sedarplus.ca. Forward-looking statements contained herein are made only as to the date of this press release and we assume no obligation to update or revise any forward-looking statements should they change, except as required by law. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

For further inquiries, please contact:

Planet 13 Investors:
Robert Groesbeck or Larry Scheffler
Co-Chief Executive Officers
ir@planet13lasvegas.com

Planet 13 Media:
Colin Trethewey / PRmediaNow Communications
Colin@PRmediaNow.com  

Politics2 days ago

Montana Lawmakers Pass Bill Allowing Cannabis Compacts Between Indian Tribes And The Governor

“It is pro-business, pro-revenue, pro-collaboration, pro-law enforcement legislation.” By Kaiden Forman-Webster, Montana Free Press Though House Bill 952 is only two pages long, it has the potential to…

New congressional marijuana bill; Gaetz’s theory on cannabis reform progress; CDC drug advice for travelers; LA legalization; NY market report

Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day.

Your support makes Marijuana Moment possible…

BREAKING: Journalism is often consumed for free, but costs money to produce! While this newsletter is proudly sent without cost to you, our ability to send it each day depends on the financial support of readers who can afford to give it. So if you’ve got a few dollars to spare each month and believe in the work we do, please consider joining us on Patreon today.
https://www.patreon.com/marijuanamoment

/ TOP THINGS TO KNOW

Reps. Dina Titus (D-NV) and Ilhan Omar (D-MN) filed a bill to repeal a federal law that requires the White House Office of National Drug Control Policy to oppose legalizing marijuana or other Schedule I drugs.

Former Rep. Matt Gaetz (R-FL), who was President Donald Trump’s first pick for attorney general this term, said there’s a “winning coalition” of Republicans and Democrats to federally legalize marijuana—but only if Democrats drop their push for social equity and “reparations.”

The U.S. Supreme Court granted a request from Solicitor General D. John Sauer for more time to decide whether the Trump administration will challenge an appeals court ruling concerning the federal prohibition on gun ownership by people who consume marijuana.

The Centers for Disease Control and Prevention published new federal guidance for international travelers about complying with local marijuana and drug laws—warning that even CBD can cause delays, denial of entry or legal issues in some countries.

The Colorado Senate Appropriations Committee amended and approved a bill to empower the governor to grant pardons to people who’ve been convicted of psychedelics-related offenses, and to revise rules for legal psychedelic products and healing centers.

A Louisiana representative said her new bill to create a marijuana legalization pilot program will provide “another revenue source” so that the state is “not constantly putting the funding” for key programs “on the back of our taxpayers.”

The New York Office of Cannabis Management published a market report showing that the number of licensed operational marijuana stores nearly tripled in 2024, with regulators reporting that total legal sales are now nearing $1.5 billion.

Nebraska lawmakers scheduled a series of town hall meetings about pending medical cannabis legislation for this weekend and next week.

/ FEDERAL

A former Drug Enforcement Administration task force officer was sentenced to nine years in federal prison for multiple offenses including conspiring to distribute narcotics.

/ STATES

Illinois Gov. J.B. Pritzker (D) touted his signing of a cannabis legalization bill as a key accomplishment during a speech at a New Hampshire Democratic Party event.

The Louisiana House Civil Law and Procedure Committee held a hearing on a bill to restrict hemp products.

Washington, D.C. regulators filed proposed changes to cannabis rules.

Alaska regulators published guidance on hemp products.

Illinois regulators published guidance about forthcoming changes to cannabis occupation tax rates.

Vermont regulators sent guidance about marijuana business event booths and off-premises displays.

Michigan regulators published a bulletin about accounting and recordkeeping best practices for marijuana businesses.

—
Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
—

/ LOCAL

A former New York City police officer authored an op-ed about her support for federal marijuana descheduling.

/ INTERNATIONAL

A Paraguayan senator discussed his support for legalizing marijuana.

/ SCIENCE & HEALTH

A study found that cannabis-based medicinal products “were associated with improvements in PTSD symptoms, anxiety, sleep, and [health-related quality of life] at up to 18 months.”

A study’s results suggested that “cannabis policy reform can alleviate law enforcement burdens and may improve racial disparities in drug seizures to a small extent yet highlight the continued necessity for policies addressing systemic biases in drug enforcement.”

/ BUSINESS

CanadaBis Capital Inc. terminated an agreement to be acquired by Simply Solventless Concentrates Ltd.

Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox.